Dopamine Agonist News and Research

RSS

New experimental treatment for Tourette's syndrome

The University of Rochester Medical Center (URMC) is leading a multi-center clinical research study of a new experimental treatment for Tourette's syndrome.The study will examine whether or not a drug that alters the chemical activity in the brain can alleviate the symptoms of the disease.

2 Dec 2008

FDA approves skin patch designed to treat symptoms of early Parkinson's disease

Rotigotine is a drug not previously approved in the United States. Neupro is the first transdermal patch approved for the treatment of symptoms of Parkinson's disease.

10 May 2007

Phase III data on Safinamide in Parkinson's disease

Merck Serono S.A. has announced that Phase III data on safinamide, a new agent in Phase III development for the treatment of Parkinson's disease symptoms, were presented by Professor Fabrizio Stocchi at the American Academy of Neurology 59th Annual Meeting in Boston, Massachusetts, USA.

4 May 2007

Jefferson participates in global study to extend effectiveness of drug for Parkinson's

After Parkinson's disease patients use the drug levodopa or L-dopa for several years as a treatment for restoring the cellular communication that controls muscle movement by replacing lost dopamine, they begin to experience motor complications that include a shortened response to each dose of L-dopa.

19 Apr 2007

Therapy for restless legs may trigger compulsive gambling

Compulsive gambling with extreme losses -- in two cases, greater than $100,000 -- by people without a prior history of gambling problems has been linked to a class of drugs commonly used to treat the neurological disorder restless legs syndrome (RLS).

11 Feb 2007

New guidelines for diagnosis and treatment of Parkinson disease

New guidelines developed by the American Academy of Neurology aim to educate physicians on the diagnosis and treatment of Parkinson disease and provide people with Parkinson disease an improved quality of life.

3 Apr 2006

Parkinson's dark period can be minimized or alleviated with the right kind of care

Some people call it "the dark time," the period between when a person is diagnosed with Parkinson's disease and when treatment with medication begins.

26 Sep 2005

Gambling and sex addiction caused by Parkinson's drug

According to a doctor at a clinic in the U.S., a certain category of drug, which is often prescribed for Parkinson's disease, can cause some patients to become compulsive gamblers or addicted to sex.

11 Jul 2005

Dopamine agonist therapy for Parkinson's disease may lead to problem gambling

Eleven patients with Parkinson's disease (PD) developed pathological gambling behavior following dopamine agonist therapy, a drug therapy to control movement problems caused by Parkinson's disease, according to a study posted online which will appear in the September print issue of Archives of Neurology.

11 Jul 2005

Clinical trial established that two drugs, levodopa and pramipexole, are both viable initial treatments for Parkinson's disease

The four-year clinical trial established that two drugs, levodopa and pramipexole, are both viable initial treatments for Parkinson's disease, a degenerative disorder of the central nervous system.

3 Aug 2004

Clinical study compares treatments in early Parkinson's disease

University of Tennessee Health Science Center professor and vice chair of the Department of Neurology, Ronald F. Pfeiffer, M.D., has been an investigator with The Parkinson Study Group (PSG), which recently reported four-year results of a major long-term, multi-center clinical trial.

21 Jul 2004

Antipsychotic compound bifeprunox worth USD 1 billion per year to Solvay and Wyeth

Solvay has re-evaluated the commercial potential of bifeprunox, a Solvay compound in clinical development for the treatment of schizophrenia . Bifeprunox additionally has the potential to be developed in other disorders, i.e. bipolar disorder.

3 Jun 2004

FDA approves new breakthrough Parkinson's drug

FDA has approved Apokyn (apomorphine) as an injectable drug for treating Parkinson's patients during episodes of "hypomobility," so-called "off periods" in which the patient becomes immobile or unable to perform activities of daily living.

21 Apr 2004